Today CTTI announced the appointments and promotions of a new leadership team including Sara Calvert as Director of Projects, Morgan Hanger as Director of Strategic Programs and Zachary Hallinan as Director of Strategic Engagement & Communications. In addition, team members Rae Holliday, Strategic Communications Manager, and Karisa Merrill, Strategic Engagement Manager, were promoted to management positions; Lindsay Kehoe was promoted to Senior Project Manager; and Erin Bland was promoted to Engagement & Communications Specialist. 

“In announcing these leadership appointments, I am proud that CTTI is able to tap into the talent, experience and passion inside CTTI and promote from within our organization,” said Sally Okun, CTTI’s Executive Director. “As we continue to drive positive change across the clinical trials enterprise, consistent performance will require a strong, diverse and talented team. These leaders, as well as our entire staff, are well prepared to lead CTTI’s most ambitious project to date, the bold Transforming Trials 2030 vision. I am confident that these appointments and promotions better position us to achieve our strategic priorities in the months and years ahead.” 

The following promotions and appointments, which collectively represent more than 25 years of service to CTTI, have gone into effect between December 2021 – March 2022: 

• Erin Bland, Engagement & Communications Specialist, provides design and management of the engagement team’s communication strategies. She participates in providing input for all new and ongoing projects to contribute to the growth and support of CTTI’s goals. She also manages logistics for CTTI member events and member communications. 
• Sara Calvert, Director of Projects, is currently responsible for senior operational leadership and oversight for the core activities of the CTTI projects group. She collaboratively develops and implements strategies to support CTTI’s project managers and multistakeholder project teams as they develop solutions to improve clinical trials, and ensures the alignment of project objectives with CTTI’s mission, vision, and goals. 
• Zachary Hallinan, Director of Strategic Engagement & Communications, provides senior operational leadership and oversight for CTTI’s strategic communications and engagement group, including collaboratively developing and implementing strategies and operational plans to support effective external communication and engagement with CTTI’s approximately 80 member organizations and the broader clinical trials enterprise. 
• Morgan Hanger, Director of Strategic Programs is leading a new initiative to develop a parsimonious set of metrics to assess, monitor, and analyze the progress of the clinical trial enterprise towards CTTI’s Transforming Trials 2030 vision, as well as advising on CTTI strategy and operations. 
• Rae Holliday, Strategic Communications Manager, is currently responsible for cultivating CTTI’s public profile through brand strategy, content development, events, media relations, and thought leadership. She is leading the development of the communications strategy for CTTI’s Transforming Trials 2030 vision in collaboration with CTTI’s communications team, DCRI writers and designers and CTTI’s agency of record. 
• Lindsay Kehoe, Senior Project Manager, manages the development and implementation of CTTI projects, as well as represents CTTI activities to internal and external audiences. She is reminded daily of the power of collaboration and innovative thinking as she convenes stakeholders around Disease Progression Modeling, Embedding Trials into Health Care Settings, advancing Digital Health Trials, and accelerates progress towards the Transforming Trials 2030 vision. 
• Karisa Merrill, Strategic Engagement Manager, currently manages CTTI’s membership and engagement team. She also plans, develops, and implements strategic initiatives that support the implementation of systematic improvement processes, drive adoption of CTTI’s recommendations and resources, and demonstrate the impact of CTTI’s work on the transformation of clinical trials.